Author/Authors :
Mie Inao، نويسنده , , Satoshi Mochida، نويسنده , , Atsushi Matsui، نويسنده , , Yuichiro Eguchi، نويسنده , , Yusufu Yulutuz، نويسنده , , Yanhong Wang، نويسنده , , KayokoNaiki، نويسنده , , Tohru Kakinuma، نويسنده , , Kenji Fujimori، نويسنده , , Sumiko Nagoshi، نويسنده , , Kenji Fujiwara، نويسنده ,
Abstract :
Background/Aims
Inchin-ko-to (TJ-135) is an herbal medicine used in Japan for treatment of icteric patients with cirrhosis. Its efficacy as an anti-fibrogenic drug was evaluated in relation to stellate cell activation.
Methods/Results
Liver fibrosis was induced in rats by repeated injections of carbon tetrachloride (CCl4) or pig-serum. Oral administration of TJ-135 improved the mortality of rats given CCl4 with reduced extents of liver necrosis and fibrosis. Similar improvement of liver fibrosis was found in rats given pig-serum showing no liver necrosis.
DNA synthesis of stellate cells activated in vitro after isolation from normal rat liver was decreased by culture with TJ-135 in a dose-related manner, accompanied by decreased smooth muscle α actin expression and contractility. Such attenuation was not found in the cells cultured with geniposide, an iridoid compound of TJ-135, but genipin, an aglycone of geniposide formed in the gut by action of bacterial flora, markedly decreased stellate cell activation without affecting synthesis of proteins other than collagen.
Conclusions
TJ-135 may be useful for treatment of liver fibrosis and portal hypertension through suppression of activated hepatic stellate cell function by genipin, an absorbed form of its component.
Keywords :
Inchin-ko-to , Liver fibrosis , TJ-135 , Hepatic stellate cells